期刊文献+

关键生物技术的研究发展趋势预见分析 被引量:1

Analysis and prospect of trends of key R&D of biotechnology
原文传递
导出
摘要 目的:结合我国在全球生物技术发展中所处的位置,对重组蛋白、单克隆抗体、疫苗、干细胞、基因治疗、组织工程、生物芯片、蛋白质组、基因组等技术领域的生物关键技术进行趋势预见分析。方法:对科学引文索引(SCI)数据库中收录的文献与专利进行年度发展演化趋势和文献集中度研究,与生物技术产业发展现状进行对比,分析生物技术从基础研究到产品上市的技术演化路径,对未来技术发展领域进行预见。结果与结论:疫苗、干细胞、蛋白质组、基因治疗领域将是未来研究持续增长、资金投向较多的生物技术上游领域,而单克隆抗体、重组蛋白、疫苗是支撑市场发展的主要产品领域。 Objective:To study nine critical technologies,i.e.,recombinant protein,monoclonal antibody,vaccine,stem cells,gene therapy,tissue engineering,gene chips,proteomics,and genomics by literature and patent data mining,and to predict the future development of these technologies.Methods:From databases of Science Citation Index(SCI) and Biosis Previews nine critical technologies based on literature and patent data mining were studied.Annual literature distribution and aggregation trends,biotechnology product and industry status were discussed.By making comparisons with current technological development,the biotechnological development roadmap was analyzed and spheres technological development were forecasted.Results and Conclusion:Vaccines,stem cells,proteomics and gene therapy will enjoy sustained development with more funds in the upstream biotechnology.Monoclonal antibodies,recombinant protein and vaccine will remain the main product types in future biotechnology markets.
出处 《军事医学科学院院刊》 CSCD 北大核心 2007年第6期538-542,共5页 Bulletin of the Academy of Military Medical Sciences
基金 北京市科委(Z0005170041691)资助项目
关键词 生物技术 技术预见 科学计量学 biotechnology technology foresight scientific bibliometrics
  • 相关文献

参考文献11

  • 1毛荐其,杨海山.技术创新进化过程与市场选择机制[J].科研管理,2006,27(3):16-22. 被引量:35
  • 2李健民.上海开展技术预见的实践与思考[J].世界科学,2003(4):44-46. 被引量:16
  • 3Kostoff RN,Toothmanb DR,Eberhart HJ.Text mining using database tomography and bibliometrics:a review[J].Technol Forecast Soc Change,2004,68 (3):223-253.
  • 4Zitt M,Barre R,Sigogneau A,et al.Territorial concentration and evolution of science and technology activities in the European Union:a descriptive analysis[J].Res Policy,1999,28 (5):545-562.
  • 5Canongia C,Antunes A,Freitas MDN.Technological foresight-the use of biotechnology in the development of new drugs against breast cancer[J].Technovation,2004,24 (4):299-309.
  • 6胡显文,陈惠鹏,汤仲明,马清钧.生物制药的现状和未来(二):发展趋势与希望[J].中国生物工程杂志,2005,25(1):86-93. 被引量:32
  • 7Editorial.Making the most of micro arrays[J].Nat Biotechnol,2006,24(9):1039-1039.
  • 8Weinstein JN,Pommier Y.Connecting genes,drugs and diseases[J].Nat Biotechnol,2006,24 (11):1365-1366.
  • 9Pompe S,Bader M,Tannert C.Stem-cell research:the state of the art.Future regulations of embryonic-stem-cell research will be influenced more by economic interests and cultural history than by ethical[J].EMBO Rep,2005,6(4):297-300.
  • 10裴国献.组织工程学——21世纪面临的机遇与挑战[J].国际骨科学杂志,2006,27(1):2-4. 被引量:14

二级参考文献37

  • 1胡显文,陈惠鹏,汤仲明,马清钧.生物制药的现状和未来(一):历史与现实市场[J].中国生物工程杂志,2004,24(12):95-101. 被引量:37
  • 2毛荐其,俞国方.技术创新进化研究综述[J].科研管理,2005,26(5):35-40. 被引量:20
  • 3毛荐其.技术创新为何进化?——一个原动力追问[J].自然辩证法研究,2006,22(2):60-62. 被引量:13
  • 4Thiel K A. Biomanufacturing, from bust to boom ... to bubble?Nature Biotechnology, 2004, 22(11): 1365-1372.
  • 5Morrison S L, Johnson M L, Herzenberg L A, et al. Chimeric human antibody molecules : mouseantigen-binding domains with human constant region domains. Proc Natl Acad Sci USA, 1984,21 : 6851-6855.
  • 6Jones P T,Dear P H,Winter G,et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature, 1986, 321 : 522-525.
  • 7McCafferty J, Griffiths A D, Winter G, et al. Phage antibodies:filamentous phage displaying antibody variable domains. Nature,1990, 348:552-554.
  • 8Green L L. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human moneelonal antibodies. J Immunol Methods,1999, 231:11-23.
  • 9Brekke O H, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nature Reviews Drug Discovery, 2003, 2:52-62.
  • 10Pavlou A,Reichert J.Monoclonal antibodies market.Nature Reviews Drug Discovery, 2004, 3:383 -384.

共引文献93

同被引文献10

  • 1中华人民共和自科学技术部.国家中长期科学和技术发展规划纲要(2006-2020年).[EB/OL].[2009.3.7].http://www.most.gov.cn/kjgh/.
  • 2中华人民共和国科学技术部.国家“十一五”科学技术发展规划.[EB/OL].[2009.3.7].http://www.most.gov.cn/mostinfo/xinxifenlei/gjkjgh/200811/t20081129-65773.htm.
  • 3王磊编著.生物制药专利对策[M].北京:军事医学科学出版社,2008:5-6.
  • 4Thomson Reuters. Thomson Data Analyzer. [ EB/OL] [ 2009. 4, 7 ] http: //thomsonreuters. com/products_ services/scientific/Thomson _ Data_ Analyzer.
  • 5Fakih M. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? [J]. Expert Rev. Anticancer T her. 2008, 8(9): 1471-1480.
  • 6Law CL, Gordon KA, Collier J el al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40[J]. Cancer Rea, 2005, 65(18): 8331-8338.
  • 7Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers Predicting Clinical Outcome of Epidermal Growth Targeted Therapy in Metastatic Colorectal [ J ] Factor Receptor - J Natl Cancer Inst,2009, 101(19): 1308-1324.
  • 8张弢,陈卫,浦迪,张娟,王旻.抗体药物研究进展与趋势[J].中国新药杂志,2008,17(9):713-718. 被引量:8
  • 9汤琳(综述),张学光(审校).CD40单克隆抗体的抗肿瘤机制及其应用[J].世界肿瘤杂志,2008,7(3):222-224. 被引量:2
  • 10刘慧龙,徐建明.EGFR单抗治疗结直肠癌研究进展[J].临床肿瘤学杂志,2008,13(10):948-953. 被引量:8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部